Lixisenatide, a Novel GLP-1 Receptor Agonist, for the Treatment of Type 2 Diabetes

Journal Title: International Journal of Health Sciences and Research - Year 2017, Vol 7, Issue 6

Abstract

Diabetes mellitus (DM) is an important global public health problem. Despite availability of many antidiabetic drugs, the glycemic goals cannot be achieved and serious complications of diabetes continue to happen. The adverse effects associated with antidiabetic medications are another issue. Glucagon like peptide-1 (GLP-1) receptor agonists are novel class of drugs, used for the treatment of type 2 DM. Recently lixisenatide is approved by United States Food and Drug Administration (US FDA) for the treatment of type 2 diabetes as add-on drug. Lixisenatide exerts its actions by acting on GLP-1 receptors, resulting in increase in insulin secretion, decrease in glucagon release, delay in gastric emptying and induction of satiety. Lixisenatide has demonstrated its clinical efficacy as antidiabetic by lowering of glycated hemoglobin (HbA1C) levels and reduction in 2 h postprandial plasma glucose (PPG) levels when used alone. Lixisenatide also has exerted synergistic antidiabetic effects when administered with metformin, sulfonylureas, pioglitazone and basal insulin in terms of greater fall in HbA1C levels and better control of 2 h PPG. Lixisenatide has been found to be non-inferior to other GLP-1 receptor agonists in reducing HbA1C and 2 h PPG with favourable side effect profile. The lixisenatide is less costly and has lower incidence of hypoglycaemia compared to exenatide and liraglutide. Overall it may serve as good add-on treatment to the existing antidiabetic drugs.

Authors and Affiliations

Amol Khanapure

Keywords

Related Articles

Complicated Pneumonia in a Case of Ataxia Telangiectasia

Ataxia Telangiectasia (AT) is a rare autosomal recessive disease with multisystemic disorder. It is characterized by progressive neurological impairment, cerebellar ataxia, variable immunodeficiency, impaired organ matur...

The Vestibular Incision Subperiosteal Tunnel Access (VISTA) for Treatment of Maxillary Anterior Gingival Recession Defects- A Case Report

Gingival recession is referred as apical shift of the gingival margin leading to the exposure of root surface to oral cavity. AAP defines marginal tissue recession as displacement of soft tissue margin apical to CEJ. It...

Physical Health Problems and Psychological Well-Being among Orphan Children of Selected Orphanage Homes

Background: Children are gift of GOD; unfortunately not all children are brought up by their parents. Most of these orphan children are placed in orphanages. Orphan means child whose mother or father or both parents are...

Epidermoid Cyst of Breast - A Common Benign Lesion, in an Uncommon Site

Epidermoid cysts are the benign lesions which occur most commonly in the scalp, back and neck. Occurrence of epidermoid cyst in the breast is very rare and only few cases have been reported in the literature. Case Report...

Seclusion: A Concept Analysis

Objective: Seclusion guided by the legal bodies, has been a measure frequently used to manage distracting and violent behaviour. Nonetheless, seclusion of mentally ill patients in a psychiatric set up has proven to be a...

Download PDF file
  • EP ID EP370311
  • DOI -
  • Views 54
  • Downloads 0

How To Cite

Amol Khanapure (2017). Lixisenatide, a Novel GLP-1 Receptor Agonist, for the Treatment of Type 2 Diabetes. International Journal of Health Sciences and Research, 7(6), 309-314. https://europub.co.uk/articles/-A-370311